louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06862401: Sequential Practicing on Psychomotor Skill Acquisition in Undergraduate Dental Students
Official title: Influence of Sequential Practicing for Psychomotor Skill Acquisition of Non-dominant Hand in Undergraduate Dental Students: A Randomized Controlled Trial With Qualitative Approach
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Undergraduate Health Professional Students
Dental Restorations
Education, Competency-Based
Dental Education and Special Care Dentistry
Dental Prosthesis
Keywords: dominant hand
sequential practice
healthcare
dental education
prosthodontic
competency
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2025-03-06
Enrollment: 28
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To determine the influence of hand practice sequence on psychomotor skill acquisition in a glass ceramic onlay preparation among undergraduate dental students.

Detailed description: Effect of bilateral transfer practice on psychomotor skill acquisition among dental students remains unresolved. Bilateral transfer assumed that training one side of the body can also improve performance on the other side. Eligible participants are fourth- to sixth-year undergraduate dental students at the Faculty of Dentistry, Chulalongkorn University during the 2024 to 2025 academic year. The participants were categorized as left- or right-handed based on self-reporting. Participants enrolled two-day study with one-week separating inverval. On the first day, they learn a video presentation on glass ceramic onlay preparation followed by two practice sessions with 2-hour within each session. The practice start with either using non-dominant or dominant hand, followed by the use of non-dominant hand. One week later, they enroll two-hour practical examination on glass ceramic onlay preparation using their non-dominant hand. No practice is allowed during one-week separating interval.

Eligibility criteria: Inclusion Criteria:

1. The fourth- to sixth-year undergraduate dental students at a single setting of school
2. The fifth- and sixth-year students had completed laboratory and lecture courses in operative and fixed dental prosthodontics
3. The fourth-year students are enrolled in their final laboratory and lecture courses in fixed prosthodontics.

Exclusion Criteria:

Undergraduate dental students who have prior experience with onlay preparation in laboratory or clinical settings or those who are unwillingness to adhere to the study protocol.

Primary outcomes:
measure: Onlay preparation score
timeFrame: 3 hours
Secondary outcomes:
measure: Qualitative measurement by focus group interview
timeFrame: 1 hours
Other outcomes:
Locations:
Study officials:
affiliation: Chulalongkorn University
name: Nareudee Limpuangthip, DDS, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00575601: Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients
Official title: Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients : A Prospective Randomized Double Blind Placebo Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Polycystic Ovary Syndrome
Keywords: pco
simvastatin
ivf
embryo transfer
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
First posted: 2007-12-18
Enrollment: 120
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether simvastatin is effective in the improvement of IVF-ICSI outcome in Pcos patients.

Detailed description: simvastatin reduces cardiovascular risks by improving hypercholesterolemia, reducing vascular smooth muscle proliferation, ameliorating inflammation, limiting theca-interstitial proliferation \& decreasing steroidogenesis (production of progesterone \& testosterone).Polycystic ovary syndrome (pcos) is associated with increased cardiovascular risks and is characterized by ovarian theca-interstitial hyperplasia\& hyperandrogenism .This study will test the hypothesis that simvastatin improves biochemical parameters\& IVF-ICSI outcome in Pcos patients.

Eligibility criteria: Inclusion Criteria:

* Pcos patients
* Age \<40 years
* FSH\<10 IU/L

Exclusion Criteria:

* Endometriosis grade 3 \&4
* History of tubal surgery
* Hydrosalpinx
* History of mellitis diabetes

Primary outcomes:
measure: ivf-et outcomes
timeFrame: 14-20 days
Secondary outcomes:
measure: Biochemical parameters baseline and 8weeks Biochemical parameters
timeFrame: baseline and 8weeks
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Imam Khomeiny Hospital
Study officials:
affiliation: Tehran University of Medical Sciences
name: batool hossein rashidi, MD
role: STUDY_CHAIR
References:
citation: Rashidi B, Abediasl J, Tehraninejad E, Rahmanpour H, Sills ES. Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial. J Investig Med. 2011 Aug;59(6):912-6. doi: 10.2310/JIM.0b013e31821bfd9c.
Clinical trial NCT03773601: Objective Sleep Behavior in Relation to a Nigth Competition in Athletes.
Official title: Objective Sleep Behavior in Relation to a Nigth Competition in Athletes: a Pilot Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep
Athlete
Sleep Deprivation
Keywords: Sleep
Athlete
Sleep Profiler
Lead sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Sponsor class: OTHER
First posted: 2018-12-12
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Sleep is a crucial factor for athletes' health and recovery. Many variables are able to negatively influence the sleep of top-level athletes, such as: anxiety, long travels, high volume or high-intensity training period, and a nigth competition too. Therefore, the aim of this pilot study is to evalute how sleep quality changes in relation to a late nigth competition in athletes.


Eligibility criteria: Inclusion Criteria:

* both genders
* age between 18 and 45
* sport activity for \> or = to 8 hours/week.
* signed informed consent

Exclusion Criteria:

* smoking
* part-time or shift worker.
* Use of medications able to influence sleep
* any medical conditions (injury) contraindicating physical exercise as diagnosed by a sports medicine physician

Primary outcomes:
measure: Sleep Efficiency
timeFrame: From the 1st to the 4th nigth of monitoring
Secondary outcomes:
measure: TQR
timeFrame: From the 1st to the 4th nigth of monitoring
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Jacopo Antonino Vitale
Study officials:
References:
Clinical trial NCT04088201: Epidermal Adhesive Sensors to Enhance Continuous Glucose Measurement in Patients With Diabetes: The EASE Study
Official title: Epidermal Adhesive Sensors to Enhance Continuous Glucose Measurement in Patients With Diabetes: The EASE Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2019-09-12
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: Self-testing of glucose by patients living with diabetes mellitus (DM) involves needles, which can cause discomfort or inconvenience; these and other factors can lead to decreased willingness to perform these checks that are vital to DM management. While technology has evolved, a needle-free glucose monitoring device is currently not available. The investigators are studying a glucose sensor that adheres to the skin, similarly to a temporary tattoo. This sensor can now obtain continuous readings. As it has not yet been tested in individuals with DM, this study will examine its accuracy and acceptability in these patients. Results from this clinical trial could serve as the basis for further development of a non-invasive, wearable glucose sensor that can provide measurements of glucose levels continuously.


Eligibility criteria: Inclusion Criteria:

* An existing diagnosis of diabetes mellitus, either T1DM or T2DM, or any other type or etiology of diabetes
* Ability to provide informed consent for participation.

Exclusion Criteria:

* Individuals without diabetes
* Those who cannot speak or read English. We are limiting participation to those who read and speak English, as this is a pilot study of a small number of participants, that will very unlikely offer the prospect of direct benefit from participating.
* Individuals who have frequent hypoglycemia, hypoglycemia unawareness, or who are at high risk for hypoglycemia.

Primary outcomes:
measure: Interstitial fluid glucose readings
timeFrame: Hourly, up to 8 hours
Secondary outcomes:
measure: Acceptablility of sensor
timeFrame: At end of study testing sessions, at 8 hours
Other outcomes:
Locations:
city: San Diego
country: United States
facility: University of California, San Diego
state: California
Study officials:
affiliation: UCSD
name: Edward C Chao, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01507701: Pilot Study for the NorCAPITAL Trial
Official title: Pilot Study for the NorCAPITAL Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Fatigue Syndrome
Keywords: adolescents
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2012-01-11
Enrollment: 5
Sex: ALL
Minimum age (years): 12
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The aim of this pilot study for the NorCAPITAL trial is to investigate the feasibility and safety of the drug clonidine in adolescent chronic fatigue syndrome (CFS). Specifically, the investigators wanted to assess appropriate dosage in relation to a) plasma concentration levels of clonidine, b) orthostatic cardiovascular responses (the pulse and blood pressure responses when rising up), and c) reports of possible adverse effects.

A possible beneficial effect of clonidine in adolescent CFS will be investigated in NorCAPITAL, which is a randomized, placebo-controlled, double blind trial.


Eligibility criteria: Inclusion Criteria:

* Persisting or constantly relapsing fatigue lasting 3 months or more
* Functional disability resulting from fatigue to a degree that prevent normal school attendance
* Age between 12 and 19 years

Exclusion Criteria:

* Another disease process or current demanding life event that might explain the fatigue
* Another chronic disease
* Permanent use of drugs
* Permanently bed-ridden
* Positive pregnancy test
* Supine systolic blood pressure (SBP) \< 85 mm Hg
* Fall in SPB upon standing \> 30 mm Hg
* Supine HR \< 50 beats/min
* Abnormal ECG

Primary outcomes:
measure: Plasma concentration level (Cmax and Co) of clonidine
timeFrame: After 14 days of treatment
Secondary outcomes:
measure: Orthostatic cardiovascular responses (head-up tilt test)
timeFrame: After 14 days of treatment
measure: Reports of adverse effects
timeFrame: Participants will be followed for the duration of treatment period, an expected average of 14 days
measure: Plasma concentration (Cmax) of clonidine
timeFrame: First day of treatment, approximately 5 hours after the first dose
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital Rikshospitalet, Dept. of Pediatrics
Study officials:
affiliation: Oslo University Hospital Rikshospitalet, Dept. of Pediatrics
name: Vegard Bruun Wyller, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Fagermoen E, Sulheim D, Winger A, Andersen AM, Vethe NT, Saul JP, Thaulow E, Wyller VB. Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial. BMC Res Notes. 2012 Aug 7;5:418. doi: 10.1186/1756-0500-5-418.
Clinical trial NCT02003001: Botulinum Toxin Injection to Prevent Ventricular Arrhythmias
Official title: Endomyocardial Botulinum Toxin Injection Can Prevent Ventricular Arrhythmias: Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Symptomatic Ventricular Asystolia
Ventricular Tachycardia
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
Sponsor class: NETWORK
First posted: 2013-12-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this prospective non-randomized study was to assess the efficacy and safety of endomyocardial botulinum toxin injection in left ventricle for preventing ventricular arrhythmias.


Eligibility criteria: Inclusion Criteria:

* symptomatic ventricular arrhythmias
* drug-resistance
* unsuccessful one or more ablation procedure with future unreasonable tries

Exclusion Criteria:

* Previous heart surgery and AF ablation procedure
* Emergency CABG
* Unstable angina or heart failure
* Use antiarrhythmic drugs within 5 elimination half-lives of the drug (or within 2 months for amiodarone)
* Requiring concomitant valve surgery
* Left ventricle ejection fraction \<35%
* Unwillingness to participate

Primary outcomes:
measure: freedom of ventricular arrhythmias
timeFrame: 1 year
Secondary outcomes:
measure: serious adverse events
timeFrame: 1 year
measure: time to recurrence of ventricular arrhythmias
timeFrame: 1 year
Other outcomes:
Locations:
city: Novosibirsk
country: Russian Federation
facility: State Research Institute of Circulation Pathology
Study officials:
References:
Clinical trial NCT01737801: Time to Perform Lung Function Test in Cystic Fibrosis
Official title: Time to Perform Lung Function Test in Cystic Fibrosis After Chest Physiotherapy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cystic Fibrosis
Keywords: Lung function
Physiotherapy
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
First posted: 2012-11-30
Enrollment: 24
Sex: ALL
Minimum age (years): 5
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Time to perform lung function test after chest physiotherapy in cystic fibrosis.

The investigators study FEV1(forced expiratory volume in one second) and FVC (forced vital capacity).

Detailed description: The patients perform spirometry before, direct after, 30 minutes, 1 hour, 2 hours, and 3 hours after physiotherapist. The investigators want to study the FEV1 and FVC.

Eligibility criteria: Inclusion Criteria:

* Patients with cystic fibrosis

Exclusion Criteria:

* patients with cystic fibrosis who could not stay at the clinic for more than 4 hrs.

Primary outcomes:
measure: Lung function test. FEV1 and FVC
timeFrame: 2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Karolinska University Hospital
Study officials:
affiliation: Karolinska Institutet
name: Cecilia Rodriguez, Physio
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01364701: Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment
Official title: A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Erectile Dysfunction
Keywords: Erectile dysfunction
combination therapy
Sildenafil
tadalafil
PDE5i
No Conditions
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2011-06-02
Enrollment: 30
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical effectiveness is of the finest tools to evaluate treatment success and is combined of 3 elements: treatment effectivity, side effect profile and patient compliance. Since the 3 main PDE5i's differ in their molecular structure, therapeutic profile and pharmacokinetics, it seems logical to assume that combining 2 different PDE5i's at lower dosage each may be beneficial in comparison to a single PDE5i maximal dose therapy. The aim of this study is to compare the clinical effectiveness of combination therapy (2 lower-dose PDE5i's) versus single maximal dose PDE5i therapy.

Detailed description: This will be a prospective, randomized, 3-arm parallel trial on 60 males with erectile dysfunction (ED) that have never been exposed to PDE5i therapy (naïve patients) will be enrolled. In each group, every patient will receive three treatment regimes (Viagra®50mg \& Cialis®10mg, Viagra®100mg, Cialis®20mg), in different sequences of administration.

Eligibility criteria: Inclusion Criteria:

* Age ranging between 35-75 years.
* Sexually active
* IIEF ED domain score 22 and below

Exclusion Criteria:

* Subjects with premature ejaculation as their main sexual complaint.
* Subjects with severe cardiovascular disease
* Subjects with Contraindications to PDE5i therapy. Namely patients receiving treatment with nitrate based medication or patients that for various reasons cannot take PDE5 inhibitors (i.e severe coronary disease, liver or renal failure, concomitant medications, etc.).

Primary outcomes:
measure: International Index of Erectile Function-Erectile Dysfunction (IIEF-ED) Domain Score
timeFrame: Every visit- altogether 3 months
Secondary outcomes:
measure: Erection Hardness Scale
timeFrame: Each visit- altogether 3 months
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus
Study officials:
affiliation: Rambam Health Care Campus
name: Yoram Vardi, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03184701: Monitoring of Symptoms and Cognitive Function Using Telehealth
Official title: Remote Monitoring of Symptoms and Cognitive Function Using Telehealth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: End Stage Liver Disease
Keywords: Telehealth
Quality of Life
Lead sponsor: Albert Einstein Healthcare Network
Sponsor class: OTHER
First posted: 2017-06-14
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: End-Stage Liver Disease (ESLD) is one of the ten leading causes of death in US. It is marked by episodic acute exacerbations of the underlying liver disease which often leads to severe symptoms, poor quality of life, mental deterioration and repeated hospitalizations.

The overall purpose of this project is to introduce a telehealth based intervention (involving remote monitoring of symptoms and cognitive function initiated at the time of discharge of ESLD patients. This will support enhanced clinical care and improve self-management in ESLD population. In addition, it will reduce healthcare utilization, improve medication adherence and overall health outcomes

Detailed description: This is a single arm study to assess the effectiveness of an experimental telehealth intervention within the treatment of ESLD, and compare it with a historic cohort. All inpatients with advanced liver disease and at least 1 complication will be eligible to participate. the study group receives the Telehealth intervention and will be given an ipad preloaded with the instruments used for symptom monitoring and cognitive function assessment during the hospital admission.

Eligibility criteria: Inclusion Criteria:

* End Stage Liver Disease with at least 1 or more complications (Hepatorenal Syndrome, Portal Hypertension, Ascites, Hepatic Encephalopathy)

Exclusion Criteria:

* Cognitive impairment
* Current psychosis

Primary outcomes:
measure: Patient Satisfaction
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Einstein Healthcare Network
state: Pennsylvania
Study officials:
affiliation: Einstein Healthcare network
name: Victor Navarro, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02629601: Evaluating Incentive Designs to Increase Physical Activity Goal Adherence in a Wellness Program
Official title: Evaluating Incentive Designs to Increase Physical Activity Goal Adherence in a Wellness Program
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Physical Activity
Keywords: physical activity
financial incentives
behavioral economics
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: Discovery Vitality
First posted: 2015-12-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a 4-week, five-arm, randomized, controlled trial to compare a standard wellness incentive program for physical activity to four other designs.

Detailed description: Increased physical activity is associated with numerous health benefits including lower risk of cardiovascular disease. However, many individuals do not achieve physical activity goals. Vitality is a wellness program in South Africa that uses a program called "Active Rewards" to incentives achievement of weekly physical activity goals. In this study, the investigators will compare the standard active rewards program to doubling the magnitude or adding lottery designs with and without broadcasting the # of winners.

Eligibility criteria: Inclusion Criteria:

* Vitality member that has activated "active rewards" program

Exclusion Criteria:

-

Primary outcomes:
measure: Proportion of participants that acheived their weekly physical activity goal
timeFrame: 4 week intervention period
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Mitesh Patel, MD, MBA, MS
role: PRINCIPAL_INVESTIGATOR
References: